scispace - formally typeset
Journal ArticleDOI

ERBB receptors and cancer: the complexity of targeted inhibitors.

TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.
Abstract
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.

read more

Citations
More filters
Journal ArticleDOI

Cancer Genome Landscapes

TL;DR: This work has revealed the genomic landscapes of common forms of human cancer, which consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of "hills" (Genes altered infrequently).
Journal ArticleDOI

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

TL;DR: In addition to their role in extracellular matrix turnover and cancer cell migration, MMPs regulate signaling pathways that control cell growth, inflammation, or angiogenesis and may even work in a nonproteolytic manner.
Journal ArticleDOI

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

TL;DR: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors, and KRAS status should be considered in selecting patients withmCRC as candidates for panitumuab mon Therapy.
References
More filters
Journal ArticleDOI

Akt kinases in breast cancer and the results of adjuvant therapy

TL;DR: Activation of the Akt pathway is correlated with erbB2 overexpression in breast cancer and the results suggest that Akt may predict the local control benefit from radiotherapy.
Journal ArticleDOI

Switching on kinases: oncogenic activation of BRAF and the PDGFR family.

TL;DR: In this article, structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the platelet-derived growth factor receptor (PDGFR) juxtamembrane region is also a frequent target.
Journal ArticleDOI

Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy

TL;DR: The purpose of the present study was to investigate the use of the chimeric MoAb cetuximab (IMC-C225), which is directed against EGFR and EGFRvIII, as a boron delivery agent for neutron capture therapy (NCT) of brain tumors.
Journal ArticleDOI

Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.

TL;DR: The epidermal growth factor (EGF) receptor and its ligands are overexpressed in human pancreatic carcinoma and may contribute to the pathophysiology of these tumors.
Journal ArticleDOI

Mechanism of 17-beta-estradiol-induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-delta.

TL;DR: E2 induces a slow but persistent activation of Erk in MCF-7 breast carcinoma cells and evaluation of downstream signaling revealed that E2-induced Erk activation is mediated by a HRG/HER-2/PKC-δ/Ras pathway that could be crucial for E1-dependent growth-promoting effects in early stages of tumor progression.
Related Papers (5)